Oncolys To Join With Bristol-Myers To Develop HIV Drug Globally
This article was originally published in PharmAsia News
Japan's Oncolys BioPharma said it has licensed to U.S.-based Bristol-Myers Squibb global rights to develop a festinavir-based HIV compound
You may also be interested in...
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.